Log in

Ultragenyx Pharmaceutical Stock Price, Forecast & Analysis (NASDAQ:RARE)

$38.57
+1.07 (+2.85 %)
(As of 11/21/2019 05:25 AM ET)
Today's Range
$37.19
Now: $38.57
$39.11
50-Day Range
$36.08
MA: $40.79
$44.94
52-Week Range
$35.41
Now: $38.57
$74.50
Volume658,800 shs
Average Volume545,160 shs
Market Capitalization$2.23 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.15
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RARE
CUSIPN/A
Phone415-483-8800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$51.49 million
Book Value$12.04 per share

Profitability

Net Income$-197,610,000.00
Net Margins-470.18%

Miscellaneous

EmployeesN/A
Market Cap$2.23 billion
Next Earnings Date2/18/2020 (Estimated)
OptionableOptionable

Receive RARE News and Ratings via Email

Sign-up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.


Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) issued its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($1.96) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.71) by $0.25. The biopharmaceutical company earned $25.80 million during the quarter, compared to analysts' expectations of $28.88 million. Ultragenyx Pharmaceutical had a negative return on equity of 52.16% and a negative net margin of 470.18%. Ultragenyx Pharmaceutical's quarterly revenue was up 119.4% compared to the same quarter last year. During the same period last year, the firm posted ($1.74) EPS. View Ultragenyx Pharmaceutical's Earnings History.

When is Ultragenyx Pharmaceutical's next earnings date?

Ultragenyx Pharmaceutical is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Ultragenyx Pharmaceutical.

What price target have analysts set for RARE?

11 brokers have issued 12 month target prices for Ultragenyx Pharmaceutical's shares. Their forecasts range from $45.00 to $87.00. On average, they expect Ultragenyx Pharmaceutical's share price to reach $71.82 in the next twelve months. This suggests a possible upside of 86.2% from the stock's current price. View Analyst Price Targets for Ultragenyx Pharmaceutical.

What is the consensus analysts' recommendation for Ultragenyx Pharmaceutical?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ultragenyx Pharmaceutical.

What are Wall Street analysts saying about Ultragenyx Pharmaceutical stock?

Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock:
  • 1. Cowen Inc analysts commented, "Matinas reported 2Q19 with net loss of ($3.6M) and ended the period with $36.8M in cash on the balance sheet. The company should have runway through 2020 and through multiple catalysts; Omega-3 (OM3) asset MAT9001 and antifungal MAT2203 (amphotericin)." (8/15/2019)
  • 2. According to Zacks Investment Research, "Ultragenyx is encouraged by the growing demand for Crysvita from both children and adults, with X-linked hypophosphatemia (XLH) in the United States. The company looks forward to expand the global commercial reach of its approved therapies in 2019. It also expects to file for potential approval of its third therapy, UX007 in fatty acid oxidation disorders in the year. Ultragenyx continues to advance the two gene therapy clinical programs — DTX401 for glycogen storage disease type Ia and DTX301 for ornithine transcarbamylase deficiency — with additional data expected to be released in 2019. However, Since Ultragenyx is a newly commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses and the need for additional capital. Loss estimates have widened ahead of the Q1 earnings results. The company has a positive record of earnings surprises in recent quarters." (4/23/2019)

Has Ultragenyx Pharmaceutical been receiving favorable news coverage?

News headlines about RARE stock have been trending positive on Thursday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ultragenyx Pharmaceutical earned a news sentiment score of 3.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Ultragenyx Pharmaceutical.

Are investors shorting Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical saw a increase in short interest in the month of October. As of October 15th, there was short interest totalling 6,090,000 shares, an increase of 7.2% from the September 15th total of 5,680,000 shares. Based on an average daily volume of 562,000 shares, the short-interest ratio is currently 10.8 days. Approximately 11.5% of the shares of the company are short sold. View Ultragenyx Pharmaceutical's Current Options Chain.

Who are some of Ultragenyx Pharmaceutical's key competitors?

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Exelixis (EXEL), Netflix (NFLX), Portola Pharmaceuticals (PTLA), Gilead Sciences (GILD), GALAPAGOS NV/S (GLPG), Palo Alto Networks (PANW), GW Pharmaceuticals PLC- (GWPH), Intercept Pharmaceuticals (ICPT), Celgene (CELG) and Esperion Therapeutics (ESPR).

Who are Ultragenyx Pharmaceutical's key executives?

Ultragenyx Pharmaceutical's management team includes the folowing people:
  • Emil D. Kakkis, President, Chief Executive Officer & Director
  • Wladimir Hogenhuis, Chief Operating Officer
  • Shalini Sharp, Chief Financial Officer & Executive Vice President
  • Dennis Karl Huang, Chief Technical Operations Officer & Senior VP
  • Eric Crombez, Chief Medical Officer

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include First Trust Advisors LP (1.73%), Sector Gamma AS (0.30%), California Public Employees Retirement System (0.20%), Rhumbline Advisers (0.14%), Mackay Shields LLC (0.08%) and State of New Jersey Common Pension Fund D (0.08%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View Institutional Ownership Trends for Ultragenyx Pharmaceutical.

Which institutional investors are selling Ultragenyx Pharmaceutical stock?

RARE stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Strs Ohio, Rhumbline Advisers and Mackay Shields LLC. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Karah Herdman Parschauer, Shalini Sharp and William Aliski. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

Which institutional investors are buying Ultragenyx Pharmaceutical stock?

RARE stock was acquired by a variety of institutional investors in the last quarter, including Sector Gamma AS, California Public Employees Retirement System, State of New Jersey Common Pension Fund D, Campbell & CO Investment Adviser LLC, SG Americas Securities LLC, First Mercantile Trust Co. and Russell Investments Group Ltd.. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $38.57.

How big of a company is Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical has a market capitalization of $2.23 billion and generates $51.49 million in revenue each year. The biopharmaceutical company earns $-197,610,000.00 in net income (profit) each year or ($7.39) on an earnings per share basis. View Additional Information About Ultragenyx Pharmaceutical.

What is Ultragenyx Pharmaceutical's official website?

The official website for Ultragenyx Pharmaceutical is http://www.ultragenyx.com/.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]


MarketBeat Community Rating for Ultragenyx Pharmaceutical (NASDAQ RARE)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  680 (Vote Outperform)
Underperform Votes:  330 (Vote Underperform)
Total Votes:  1,010
MarketBeat's community ratings are surveys of what our community members think about Ultragenyx Pharmaceutical and other stocks. Vote "Outperform" if you believe RARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel